Scheduling and Rescheduling Controlled Substances
Delia Ann Deschaine
Partner
Epstein Becker Green
Matthew C. Zorn
Partner
Yetter Coleman LLP
- Reviewing the legal pathways to scheduling and rescheduling: administrative and legislative
- Assessing the credibility and reliability of the data and evidence used in the scheduling process
- Strategies for demonstrating a drug has little or no potential for abuse
- Assessing the credibility and reliability of the data and evidence used in the scheduling process
- Historical review of drugs that have been scheduled legislatively (e.g., gamma-hydroxybutyric acid, a date rape drug)
- Understanding how and when public petitions for administrative scheduling occur (e.g., the 2002 rescheduling of buprenorphine)
- An update on the challenge to DEA’s rescheduling petition denial (Right to Try) in the U.S. Court of Appeal’s 9th circuit
- Considering international treaties in the context of rescheduling